Dose-intensive weekly combination chemotherapy (cisplatin, vincristine, doxorubicin and etoposide) followed by cisplatin-etoposide therapy with concurrent thoracic irradiation: evaluation of a new treatment for limited-disease small-cell lung cancer.
Not Applicable
- Conditions
- limited-disease small-cell lung cancer
- Registration Number
- JPRN-C000000145
- Lead Sponsor
- West Japan Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
The criteria were age ≥ to 18 years and ≤ 70years, no concurrent active malignancies.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method